Design Therapeutics (DSGN) Shares Outstanding (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Shares Outstanding (Entity) of $62.6 million for Q2 2026, up 9.89% year-over-year from $56.9 million in Q2 2025, and little changed on a QoQ basis from $62.4 million in Q1 2026.
Design Therapeutics (DSGN) Shares Outstanding (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $62.6 million in Q2 2026.
- Shares Outstanding (Entity) for Q2 2026 came in at $62.6 million, up 9.89% year-over-year; the trailing twelve-month figure through Jun 2026 was $62.6 million (up 9.89% YoY), and the FY2025 annual result was $60.4 million, up 6.42% from the prior year.
- Shares Outstanding (Entity) was little changed at $62.6 million in Q2 2026, from $62.4 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $62.6 million in Q2 2026 and troughed at $55.6 million in Q1 2022.
- A 5-year average of $57.2 million and a median of $56.6 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The widest annual swing landed in 2022, when Shares Outstanding (Entity) surged 215.47%; it then advanced 0.28% in 2023.
- A 5-year view of Shares Outstanding (Entity) shows it stood at $55.9 million in 2022, then gained by 1.03% to $56.5 million in 2023, then rose by 0.5% to $56.8 million in 2024, then advanced by 6.42% to $60.4 million in 2025, then increased by 3.62% to $62.6 million in 2026.
- Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $62.6 million in Q2 2026, $62.4 million in Q1 2026, and $60.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | 62.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.51 Mn |
| Mar 31, 2026 | 61.43 Mn |
| Dec 31, 2025 | 57.33 Mn |
| Sep 30, 2025 | 56.95 Mn |
| Jun 30, 2025 | 56.86 Mn |
| Mar 31, 2025 | 56.76 Mn |
| Dec 31, 2024 | 56.59 Mn |
| Sep 30, 2024 | 56.62 Mn |
| Jun 30, 2024 | 56.56 Mn |
| Mar 31, 2024 | 56.49 Mn |
| Dec 31, 2023 | 55.98 Mn |
| Sep 30, 2023 | 55.99 Mn |
| Jun 30, 2023 | 55.95 Mn |
| Mar 31, 2023 | 55.91 Mn |
| Dec 31, 2022 | 55.71 Mn |
| Sep 30, 2022 | 55.78 Mn |
| Jun 30, 2022 | 55.67 Mn |
| Mar 31, 2022 | 55.51 Mn |
| Dec 31, 2021 | 45.94 Mn |
| Sep 30, 2021 | 55.16 Mn |